PRA was awarded a rheumatoid arthritis study contract based on our strategy for achieving first-patient-in (FPI) by the end of the calendar year. PRA’s plan depended on a closely managed project with clear timelines and responsibilities, as well as selecting key sites that could support our goal. PRA reduced the project’s cost by approximately 15% through our ability to enroll the targeted number of patients with fewer sites and in a shorter time period.
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
Targeting Patients In A Complex Phase II Rheumatoid Arthritis Study
Targeting Patients In A Complex Phase IIa Rheumatoid Arthritis Study.
We are experienced therapeutic professionals delivering expertise, effective leadership, and strategic operational services to immunology clinical…